- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04805788
Stereotactic Body Proton Radiotherapy for the Treatment of Liver Cancer
A Phase II Single Arm Trial of Stereotactic Body Proton Radiotherapy (SBPT) for Hepatocellular Carcinoma
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
PRIMARY OBJECTIVE:
I. To determine the 3-month rate of patients experiencing an increase in Child-Pugh (CP) score by 2 or more points of 5-fraction stereotactic body proton radiotherapy (SBPT) in the treatment of hepatocellular carcinoma (HCC).
SECONDARY OBJECTIVES:
I. To determine the 3-month complication rate as defined by grade 3 or higher acute adverse event.
II. To assess late toxicity with 2 year follow-up. III. To estimate the 6-month local control, liver disease control, progression free survival and overall survival.
IV. To determine objective imaging response rates at 6 months by Modified (m) Response Evaluation Criteria in Solid Tumors (RECIST) and RECIST criteria.
V. To determine the value of volumetric imaging analysis compared to mRECIST and RECIST in the setting of HCC treated with stereotactic body radiotherapy (SBRT).
CORRELATIVE AND EXPLORATORY OBJECTIVES:
I. To evaluate patient-reported outcomes. II. To evaluate clinical features, treatment technique, and dose-volume parameters associated with better local control and fewer adverse events.
III. To determine the value of additional imaging analyses and techniques for assessing tumor response after treatment with SBRT IV. To blood bank patient specimens for future analysis.
OUTLINE:
Patients undergo 1 SBPT fraction over 20-30 minutes per day for a total of 5 fractions.
After completion of study treatment, patients are followed up at 2 weeks, 3 , 6, 12 and 24 months, then annually for 3 years.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Arizona
-
Scottsdale, Arizona, United States, 85259
- Mayo Clinic in Arizona
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Mayo Clinic in Rochester
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age >= 18 years
- Radiologically presumed or histologically proven, newly diagnosed or recurrent, hepatocellular carcinoma
Clinical stage T0-T4N0M0 (American Joint Committee on Cancer [AJCC] 8th edition).
- One to three discrete Liver Reporting and Data System-5 (LIRADS-5) lesions that can be encompassed within a single radiation treatment plan
- Patients treated with external beam radiation as a bridge to transplant are allowed
- Minimum single lesion size >= 1 cm, maximum cumulative diameter =< 15 cm
- Vascular involvement (including portal vein, inferior vena cava [IVC] and/or hepatic vein) is allowed
- Target lesion must be amenable to a SBRT regimen utilizing proton beam therapy (i.e. SBPT)
- Prior local liver treatment including surgery, percutaneous ablation, transarterial bland or chemoembolization (TACE), or Y-90 radioembolization is allowed if completed at least 6 weeks prior to treatment start date
- Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 to 2
- Life expectance >= 3 months based on medical comorbidities, tumor extent and other clinical factors as determined by treating physician
- Child Pugh score of A or B7
- Absolute neutrophil count (ANC) >= 1000 cells/mm^3 (within 45 days of study entry)
- Platelets (Plt) >= 30,000 cells/mm^3 (the use of transfusion or other intervention to achieve the minimum platelet level is allowed) (within 45 days of study entry)
- Hemoglobin (Hgb) >= 8.0 g/dL (the use of transfusion or other intervention to achieve the minimum hemoglobin level is allowed) (within 45 days of study entry)
- Total bilirubin < 2 mg/dL (within 45 days of study entry)
- Able to and provides Institutional Review Board (IRB) approved study specific written informed consent
- Willing to return to enrolling institution for follow-up (during the active monitoring phase of the study)
- Enrollment on a second independent protocol is allowed if the second protocol intervention will not significantly affect results of the current protocol as determined by the study investigators
Exclusion Criteria:
- Medical contraindication to receipt of radiotherapy
- Severe active co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens
- Uncontrolled concurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements or providing informed consent
- Active systemic lupus or scleroderma
- Women of childbearing potential who are sexually active and not willing/able to use medically acceptable forms of contraception
- Prior receipt of external beam radiation to the current active disease site or if additional radiotherapy to the current site would be unsafe as determined by the treating radiation oncologist
- More than 3 LIRADS-5 lesions or disease extent such that organ at risk constraints cannot be met
- Tumor extension into common or main branch biliary duct or adjacent organs including stomach, small or large bowel
- Extrahepatic metastases or lymph node involvement
- History of other malignancies (except for in situ cancers treated only by local excision and basal cell and squamous cell carcinomas of the skin) within 1 year prior to study entry
- Patient is unable to undergo intravenous contrast enhanced liver imaging (either computed tomography [CT] or magnetic resonance imaging [MRI]) based on clinical imaging protocols established at the treating institution
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment (SBPT)
Patients undergo 1 SBPT fraction over 20-30 minutes per day for a total of 5 fractions.
|
Ancillary studies
Other Names:
Undergo SBPT
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
3-month rate of patients experiencing an increase in Child-Pugh score by 2 or more points of 5-fraction stereotactic body proton radiotherapy in the treatment of hepatocellular carcinoma (HCC)
Time Frame: 3 months
|
The rate will be estimated and a 95% exact binomial confidence interval reported, and then tested utilizing a one-sample test for proportions versus the historical control of 15%.
|
3 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
3-month complication rate
Time Frame: 3 months
|
Defined by grade 3 or higher acute adverse event.
Will be calculated and presented with 95% confidence intervals (CI), while continuous outcomes will be presented with mean, median, 95% CI, and interquartile range (IQR).
|
3 months
|
Incidence of late toxicity
Time Frame: Up to 2 years
|
Defined by grade 3 or higher acute adverse event.
|
Up to 2 years
|
6-month local control
Time Frame: 6 months
|
Will be reported via Kaplan-Meier estimates.
|
6 months
|
Liver disease control
Time Frame: Up to 2 years
|
Will be reported via Kaplan-Meier estimates.
|
Up to 2 years
|
Progression free survival
Time Frame: Up to 2 years
|
Will be reported via Kaplan-Meier estimates.
|
Up to 2 years
|
Overall survival
Time Frame: Up to 2 years
|
Will be reported via Kaplan-Meier estimates.
|
Up to 2 years
|
Imaging response rates
Time Frame: 6 months
|
Will be determined by Modified (m) Response Evaluation Criteria in Solid Tumors (RECIST) and RECIST criteria.
Will be calculated and presented with 95% CI, while continuous outcomes will be presented with mean, median, 95% CI, and IQR.
|
6 months
|
Value of volumetric imaging analysis
Time Frame: 6 months
|
Will be compared to mRECIST and RECIST in the setting of HCC treated with stereotactic body radiotherapy (SBRT).
|
6 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Patient-reported outcomes
Time Frame: Up to 2 years
|
Will be evaluated per the validated measure and presented over time with means and 95% CIs.
|
Up to 2 years
|
Clinical features, treatment technique, and dose-volume parameters
Time Frame: Up to 2 years
|
Will be associated with better local control and fewer adverse events.
|
Up to 2 years
|
Value of additional imaging analyses and techniques
Time Frame: Up to 2 years
|
Will be determined assessing tumor response after treatment with SBRT.
|
Up to 2 years
|
Blood bank patient specimens for future analysis
Time Frame: Up to 2 years
|
Up to 2 years
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Jonathan B. Ashman, M.D., Ph.D., Mayo Clinic
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- MC200804 (Other Identifier: Mayo Clinic in Arizona)
- NCI-2021-01357 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
- 20-005638 (Other Identifier: Mayo Clinic Institutional Review Board)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Recurrent Hepatocellular Carcinoma
-
Emory UniversityNational Cancer Institute (NCI); Eisai Co., Ltd.RecruitingUnresectable Hepatocellular Carcinoma | Recurrent Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC... and other conditionsUnited States
-
National Cancer Center, KoreaCompletedRecurrent Small Hepatocellular Carcinoma | Residual Small Hepatocellular CarcinomaKorea, Republic of
-
Southwest Hospital, ChinaRecruitingHepatocellular Carcinoma RecurrentChina
-
Ming ZhaoRecruitingRecurrent Hepatocellular CarcinomaChina
-
Sun Yat-sen UniversityRecruitingRecurrent Hepatocellular CarcinomaChina
-
Lion TCR Pte. Ltd.Third Affiliated Hospital, Sun Yat-Sen University; Agency for Science, Technology...UnknownRecurrent Hepatocellular CarcinomaChina
-
Sun Yat-sen UniversityCompletedRecurrent Hepatocellular Carcinoma
-
Xiaoshun HeLion TCR Pte. Ltd.UnknownRecurrent Hepatocellular CarcinomaChina
-
Eastern Hepatobiliary Surgery HospitalCompletedRecurrent Hepatocellular CarcinomaChina
-
OHSU Knight Cancer InstituteOregon Health and Science UniversityWithdrawnUnresectable Hepatocellular Carcinoma | Recurrent Hepatocellular Carcinoma | BCLC Stage B Hepatocellular Carcinoma | BCLC Stage C Hepatocellular Carcinoma | Locally Advanced Hepatocellular Carcinoma
Clinical Trials on Quality-of-Life Assessment
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)CompletedUnspecified Adult Solid Tumor, Protocol Specific | Malignant NeoplasmUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)RecruitingChildhood Malignant NeoplasmUnited States, Canada, Puerto Rico, Australia, New Zealand
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)CompletedOvarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Serous Cystadenocarcinoma | Stage IV Ovarian Germ Cell Tumor | Ovarian Sarcoma | Malignant Ovarian Epithelial Tumor | Ovarian Carcinosarcoma | Ovarian Brenner Tumor | Ovarian Mucinous... and other conditionsUnited States
-
Wake Forest University Health SciencesWithdrawnLung Metastases | Extensive Stage Small Cell Lung Cancer | Recurrent Small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer | Recurrent Malignant Mesothelioma | Advanced Malignant Mesothelioma
-
City of Hope Medical CenterNational Cancer Institute (NCI)Recruiting
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm | COVID-19 InfectionUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm | COVID-19 InfectionUnited States
-
M.D. Anderson Cancer CenterActive, not recruitingCervical Carcinoma | Endometrial Carcinoma | Vaginal Carcinoma | Malignant Female Reproductive System Neoplasm | Vulvar CarcinomaUnited States
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)Active, not recruitingMetastatic Colorectal Carcinoma | Stage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC v8 and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm | Neuropathy | COVID-19 InfectionUnited States